Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor

Abstract

BackgroundReceptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) is a chondroitin sulphate (CS) transmembrane protein tyrosine phosphatase and is a receptor for pleiotrophin (PTN). RPTPβ/ζ interacts with ανβ3 on the cell surface and upon binding of PTN leads to c-Src dephosphorylation at Tyr530, β3 Tyr773 phosphorylation, cell surface nucleolin (NCL) localization and stimulation of cell migration. c-Src-mediated β3 Tyr773 phosphorylation is also observed after vascular endothelial growth factor 165 (VEGF165) stimulation of endothelial cells and is essential for VEGF receptor type 2 (VEGFR2) - ανβ3 integrin association and subsequent signaling. In the present work, we studied whether RPTPβ/ζ mediates angiogenic actions of VEGF.MethodsHuman umbilical vein endothelial, human glioma U87MG and stably transfected Chinese hamster ovary cells expressing different β3 subunits were used. Protein-protein interactions were studied by a combination of immunoprecipitation/Western blot, immunofluorescence and proximity ligation assays, properly quantified as needed. RPTPβ/ζ expression was down-regulated using small interference RNA technology. Migration assays were performed in 24-well microchemotaxis chambers, using uncoated polycarbonate membranes with 8 μm pores.ResultsRPTPβ/ζ mediates VEGF165-induced c-Src-dependent β3 Tyr773 phosphorylation, which is required for VEGFR2-ανβ3 interaction and the downstream activation of phosphatidylinositol 3-kinase (PI3K) and cell surface NCL localization. RPTPβ/ζ directly interacts with VEGF165, and this interaction is not affected by bevacizumab, while it is interrupted by both CS-E and PTN. Down-regulation of RPTPβ/ζ by siRNA or administration of exogenous CS-E abolishes VEGF165-induced endothelial cell migration, while PTN inhibits the migratory effect of VEGF165 to the levels of its own effect.ConclusionsThese data identify RPTPβ/ζ as a cell membrane binding partner for VEGF that regulates angiogenic functions of endothelial cells and suggest that it warrants further validation as a potential target for development of additive or alternative anti-VEGF therapies.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-015-0287-3) contains supplementary material, which is available to authorized users.

Meeting the needs of breast cancer: A nucleolin’s perspective

“…Interestingly, VEGF was shown to induce the translocation of nucleolin from the nucleus to the cell membrane, through the activation of a signaling pathway involving receptor protein tyrosine phosphatase b/z (RPTPb/z), which culminates in nucleolin phosphorylation by PI3K 296 . Phosphorylation regulates nucleolin's subcellular localization, and has been correlated with metastatic potential in various carcinomas 254 .…”

A minimally invasive endovascular rabbit model for experimental induction of progressive myocardial hypertrophy

“…The decrease of VEGF expression was further verified by western blot analysis of tissue protein extracts. At the same time, the expression of PTN, which has been shown to limit VEGF functions, 9,10 was significantly increased in the Stent group as compared with the Control group (Figure 7).…”

Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease

“…On the other hand, Ptn directly binds to VEGF and inhibits VEGF-induced endothelial proliferation and tube formation [58]. Another group reported that VEGF bound to RPTPβ/ζ and that Ptn interrupted this binding to inhibit VEGF-induced endothelial migration [59, 60]. Additionally, Ptn suppressed the expression of VEGF receptor 2 (VEGFR2), thereby inhibiting VEGF-induced endothelial proliferation and migration [61].…”